Entasis Therapeutics Holdings ETTX
$ 2.19
0.0%
Quarterly report 2022-Q1
added 12-23-2023
Country |
USA |
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Dr. Manoussos Perros |
Employees in the company |
48 |
Shares |
43.3 M |
Market Cap[1] |
$ 105 M |
EBITDA (LTM) |
$ -55.5 M |
P/E (LTM) |
-1.89 |
P/S (LTM) |
-21.85 |
EPS (LTM) |
-1.16 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.